GLP-1 can mean a natural peptide, a laboratory measurement or an entire class of medicines in everyday discussion. Those meanings are related but not interchangeable. For reading research, the useful starting point is the actual molecular form. Its residue interval and terminal chemistry identify what was measured or administered, before questions about receptors or clinical outcomes arise.
Read the complete form name
The IUPHAR/BPS Guide to Pharmacology maintains separate entries for GLP-1(7–36) amide and GLP-1(7–37). Both are linked to the GCG precursor record and identified as endogenous peptides.IUPHAR/BPS — GLP-1(7–36) amide (opens in a new tab)IUPHAR/BPS — GLP-1(7–37) (opens in a new tab)
| Form | Residue count | Detail to preserve |
|---|---|---|
| GLP-1(7–36) amide | 30 | The amidated carboxyl terminus |
| GLP-1(7–37) | 31 | The extra terminal residue and its chemical form |
These lengths come from counting both endpoints of the stated interval. The notation does not mean that the first form contains 36 residues. Nor should the positions be transferred directly to an unprocessed precursor without checking its numbering.
If a methods section says only GLP-1, inspect the reagent description or analytical target. A missing suffix may be harmless shorthand after a full definition, but it leaves an unresolved identity question when no definition appears.
A precursor signal is not always a mature hormone signal
Ørskov and colleagues examined human pancreatic and intestinal extracts in 1987 using immunoassays and chromatography. GLP-related immunoreactivity occurred mainly in a larger molecular form in the pancreas and in separate smaller forms in the intestine.Ørskov and colleagues — Pancreatic and intestinal processing of proglucagon in man (opens in a new tab)
The study illustrates why detecting a recognisable region of a precursor does not necessarily identify the free mature peptide. The same antibody-recognised region can be present within molecules of different sizes.
For a modern concentration result, ask whether the assay recognises the intended intact form, a shared region or a combination of forms. The answer determines what the reported number describes.
What the early human studies established
Kreymann and colleagues’ 1987 study found meal-related changes in GLP-1(7–36)-like immunoreactivity and examined the amidated peptide in seven volunteers. It observed insulin, glucose and glucagon responses under defined experimental conditions.Kreymann and colleagues — GLP-1 7–36 as a physiological incretin (opens in a new tab)
A later direct comparison by Ørskov, Wettergren and Holst studied six healthy volunteers. The two endogenous forms produced similar measured endocrine and metabolic responses, without statistically significant differences in the reported comparisons.Ørskov, Wettergren and Holst — Direct comparison of the two GLP-1 forms (opens in a new tab)
That result supports similarity for those measurements in that small study. It is not proof that the molecules are chemically identical or equivalent for every tissue, exposure pattern and outcome.
The studies help establish physiological context. They do not supply a long-term body-weight result, a modern medicine trial or evidence about an unspecified commercial preparation.
Separate the reference hormone from a receptor-agonist category
When a new paper concerns a GLP-1 receptor agonist, record its actual compound name in a separate field from the receptor. The receptor category explains a relationship; the compound entry identifies the intervention.
Then distinguish endogenous secretion, administration of a native form and testing of a modified analogue. They change different parts of the biological system and cannot be counted as repeated versions of one experiment.
A concise evidence note might state: a defined native form changed a measured hormone response in healthy volunteers. It should not become: all GLP-1 products produce the same clinical benefit.
This reference is a foundation for interpreting the literature. Product-specific efficacy, formulation and regulatory questions require evidence about the exact product and remain outside its scope.
Sources and further detail
- IUPHAR/BPS — GLP-1(7–36) amide (opens in a new tab)
Curated endogenous identity, precursor mapping and terminal form checked. No clinical claim taken from a ligand entry.
- IUPHAR/BPS — GLP-1(7–37) (opens in a new tab)
Separate endogenous-form record checked. Inclusive residue counts are original arithmetic.
- Ørskov and colleagues — Pancreatic and intestinal processing of proglucagon in man (opens in a new tab)
Original indexed abstract read for tissue extracts, chromatography and molecular-size differences.
- Kreymann and colleagues — GLP-1 7–36 as a physiological incretin (opens in a new tab)
Original 1987 abstract read. Seven-person physiological study retained without administration instructions or long-term benefit claims.
- Ørskov, Wettergren and Holst — Direct comparison of the two GLP-1 forms (opens in a new tab)
Original 1993 paper abstract, participant methods and results read in an indexed public exhibit copy; publication metadata cross-checked with the authors’ university record. Non-significance is not universal equivalence.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.